The growth of erythroid colonies (from erythroid colonyforming cells) and erythroid bursts (from burst-forming cells IBFU-EI) is enhanced in the presence of serum as compared with plasma. A significant proportion of the enhanced growth is due to the platelet release product, platelet-derived growth factor (PDGF). Colony growth in cultures of whole marrow cells in platelet-poor plasma-derived serum (PDS) and erythropoietin was enhanced in a dose-dependent fashion by increasing concentrations of purified human PDGF with optimal enhancement at 12.5 ng/ml. However, no effect of plateletrelease products or PDGF was observed on nonadherent human marrow cells or peripheral blood BFU-E, suggesting that an accessory cell population was required for the effect of PDGF on hematopoietic progenitors. In a two-layer culture system, pure populations of fibroblasts or smooth muscle cells, known to be present in the marrow microenvironment, restored the response of nonadherent marrow cells in the overlayer to PDGF and also conferred responsiveness to peripheral blood BFU-E. Endothelial cells in the two-layer culture system and macrophages, in contrast, lacked the ability to restore the enhancing effect of PDGF. Because other platelet-release mitogenic products are also found in serum, a monospecific anti-PDGF IgG preparation was added to cultures grown in platelet rich plasma-derived serum. Only partial reduction in colony and burst growth was seen, suggesting that other platelet-release products were acting in this system. These results demonstrate that PDGF enhancement of human hematopoietic progenitor cell growth requires mesenchymal cells, and provide an example and mechanism by which growth factors may influence hematopoietic progenitors via cells of the marrow microenvironment.
Introduction
Recently it has been reported that platelet-derived growth factor (PDGF)' enhances erythropoiesis when added to cultures of human marrow cells (1) . Since no specific PDGF receptor Dr. Delwiche was the recipient of a Scientific Medical Research Foundation Award from the Fonds de la Recherche Scientifique Medicale, Brussels, Belgium.
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1. Abbreviations used in this paper: BFU-E, burst-forming cells; CFU-E, erythroid colony-forming cells; Ep, erythropoietin; FCS, fetal calf serum; PDGF, platelet-derived growth factor, PDS, platelet-poor plasmaderived serum; PRS, platelet-rich plasma-derived serum.
has been demonstrated on lymphoid cells (2) , and since PDGF has been shown to be specific for connective tissue cells (2, 3) , we investigated the mechanisms underlying the enhancing properties of PDGF and other platelet-release products on human erythroid progenitor growth.
Our studies confirm that human erythroid colony and erythroid burst growth in vitro is enhanced both by products of platelet release and purified PDGF. However, our data suggest that PDGF is not the only platelet-derived factor capable of stimulating in vitro erythropoiesis, and that the enhancing effect of PDGF, itself, is dependent upon a population of adherent cells in the marrow.
Methods
Preparation ofplatelet-poor plasma-derived serum (PDS) and platelet-rich plasma-derived serum (PRS)
Blood was drawn into an ice-cold plastic syringe containing 7.6% sodium citrate to give a final concentration of 0.38% (vol/vol). The sample was mixed and centrifuged at 200 g for 15 min at 4°C to remove erythrocytes and nucleated cells. The supernatant (platelet-rich plasma) was removed and divided into two equal portions. One portion, to be used to make platelet-rich serum, was left at room temperature. The other portion was recentrifuged at 11,000 g for I h at 4°C and the supernatant, the platelet-poor plasma, was removed. To promote clotting, CaCl2 was added to each plasma at a final concentration of 12 
Erythroid colony assay
Erythroid colony-and burst-forming cells (CFU-E and BFU-E, respectively), were cultured in methylcellulose using a modification of the technique originally described by Iscove et al. (7) . 1 with an inverted microscope. Aggregates of eight or more hemoglobinized cells were scored as CFU-E-derived colonies. After 13 d of incubation, the same plates were examined and aggregates comprised of 50 or more hemoglobinized cells or three or more clusters of hemoglobinized cells were scored as BFU-E-derived colonies. When all experiments were analyzed, the cloning efficiencies for CFU-E-and BFU-E-derived marrow colonies were 133±13 (SEM) and 53±5 per 101 cells plated, respectively, and were optimal in 30% FCS.
Peripheral blood mononuclear cells were plated at a concentration of 2.5 X 105/ml and cultured in the same conditions described above. BFU-E-derived colonies were scored after 11 d of incubation. To study the interactions between PDGF and other cell types, a two-layer culture technique was used in which 103 fibroblasts, smooth muscle cells, or endothelial cells were allowed to adhere for 2 h to the bottom of the culture dish, the medium decanted, and then 1.0 ml of media in 0.5% agar was added. The overlayer contained 10' nonadherent marrow cells in 1.0 ml of the same methylcellulose mixture as described above.
PDGF and anti-PDGF antibody
Highly-purified PDGF was prepared as described by Raines and Ross (8) and radioiodinated using the iodine monochloride method described by Bowen-Pope and Ross (3) . Protein concentrations were determined by the method of Lowry et al. (9) using BSA as a standard. The purity of the PDGF was determined to be 93% by scans of silver stained gels (8) , and by determination of the fraction of '251-PDGF capable of specific, high-affinity binding to cultured cells (3) . The PDGF preparation was dissolved in I mM acetic acid and diluted in alpha medium supplemented with BSA (final BSA concentration of 2 mg/ml).
Monospecific antiserum to PDGF was prepared in a goat using purified antigen (8) . The anti-PDGF removes PDGF activity from PRS as determined by PDGF competitive activity in the radioreceptor assay, and does not recognize platelet factor 4, ,B-thromboglobulin, or thrombospondin (three other alpha granule constituents) by radioimmunoprecipitation, nor does it alter the mitogenic activity of three other known growth factors-insulin, epidermal growth factor, or 2. The Ep used in these experiments was partially purified in our laboratory from urine pooled from a patient with pure red cell aplasia. The purification scheme is a modification of that reported by Iscove et al. (7), which includes concanavalin A chromatography to reduce colony-stimulating and erythroid burst-promoting activities. This Ep preparation lacked inhibition of erythroid colony or burst growth at concentrations of up to 5.0 and 10.0 U/ml culture, respectively. fibroblast growth factor. The IgG fraction was purified by Na2SO4 precipitation and chromatography on DEAE-Sephacel. The IgG fraction from a nonimmunized goat was prepared by the same procedure.
Determination of PDGF levels PDGF levels were determined in PDS, PRS, and FCS by a modification of the radioreceptor assay described by Bowen-Pope and Ross (3) . Subconfluent cultures of human foreskin fibroblasts were plated in 1% human PDS in 2 cm2 Costar (Costar, Cambridge, MA) 24-well culture dishes. The media were aspirated, the cells washed once, and the media replaced with 1.0 ml/well of ice-cold binding medium (Hepesbuffered Ham's medium F12 [Gibco Laboratories, Grand Island, NY] adjusted to pH 7.4) containing 2% (vol/vol) calf CMS-I (calf serum incubated with CM-Sephadex to remove PDGF) (10) and the sera to be tested, or standard concentrations of pure unlabeled PDGF. The cultures were incubated at 40C on an oscillating table for 3 h. The test solutions were then removed by aspiration, the wells rinsed once with phosphate-buffered saline (PBS) containing 0.1% BSA, and then allowed to incubate for an additional hour at 4VC with 1.0 ml/well of binding medium containing 0.5 ng '351-PDGF/ml. The '25I-PDGF bound was determined as previously described (3), and the PDGF content of an unknown sample determined from a standard curve of purified PDGF.
Data analysis
To compare results between experiments, colony numbers were normalized to control cultures. The data presented are based on three or more separate experiments performed in triplicate (12 cultures/point).
The P values for statistical significance were obtained from the F test for treatment effect of a repeated measures design.
Results
Comparison of erythroid colony growth and PDGF levels in PDS and PRS. To define the requirement for plasma components to optimize erythroid colony growth in the absence of platelet-release factors, plating efficiencies were determined in the presence of increasing concentrations of PDS. Under all conditions studied, erythroid colonies were observed only when Ep was added to the cultures, and optimal growth of erythroid colonies was observed in the presence of 30% FCS. The greatest numbers of erythroid colonies in plasma were observed with 5% PDS (Fig. 1) . Under these conditions, the cloning efficiencies for CFU-E-and BFU-E-derived colonies were 67.0±7.0 (SEM) and 16.0±2.0 per 105 marrow cells plated, respectively. Fig. 2 demonstrates that 5% PRS, which contains plateletrelease factors, more effectively supported erythroid colony growth from marrow than did the optimal plasma concentration, 5% PDS. The enhancing effects seen for PRS over PDS on CFU-E and BFU-E growth were similar (+50 and +47%, respectively). However, when compared with the in vitro conditions of growth in 30% FCS, the recovery for CFU-E was higher than for BFU-E (84% of optimal numbers vs. 57%). Contrary to the results obtained with marrow cells, the presence of platelet-release products in PRS did not enhance the growth of peripheral blood BFU-E compared with PDS (data not shown). The levels of one platelet component, PDGF, were determined by radioreceptor assay (3) for each serum used. FCS contained 1.25 ng/ml (0.36 ng/culture in 30% FCS), PRS contained 14.0 ng/ml (0.7 ng/culture in 5% PRS), and PDS contained no detectable PDGF (<0.04 ng/ml).
Effect of a PDGF antibody on the enhancing properties of PRS. To determine if the enhancing effects of PRS were due solely to PDGF, the PDS and PRS were incubated for 1 h at 370C with a goat anti-human PDGF IgG preparation. The erythroid burst (.) and erythroid colony (o) growth. The erythroid colony assay was performed as described in Methods, and all cultures contained 1.5 U Ep/ml. Optimal colony numbers were consistently seen at 5% PDS concentration (100% erythroid colony growth). Under these conditions, the mean (±SEM) cloning efficiencies for CFU-E-and BFU-E-derived colonies were 67 (±7.0) and 16 (±2.0) per 10i marrow cells plated, respectively. The graph represents the mean±SEM for three separate experiments carried out in triplicate. monospecific anti-PDGF IgG, at a concentration of 20 jg/ml, completely inhibited 1 ng/ml purified PDGF or an equivalent amount of PDGF in PRS, as determined by assay of mitogenic activity or ability to compete with '23I-PDGF in the radioreceptor assay (data not shown).
The concentration of IgG used in experiments, shown in Fig. 2 , was based on the serum level of PDGF determined by radioreceptor assay, and either a three-or sixfold excess was used (i.e., for a PDGF level of I ng/ml, either 60 or 120 fsg/ ml of anti-PDGF IgG was used). In the effects of a three-or sixfold excess of the antibody gave similar results. Neutralizing concentrations of anti-PDGF antibody (sixfold excess) had no effect on CFU-E or BFU-E growth in PDS, while the same concentration inhibited colony growth in PRS by 66 and 37% for CFU-E and BFU-E, respectively (Fig. 2) . Equivalent concentrations of nonimmune goat IgG had no effect on CFU-E or BFU-E growth in PRS or PDS (data not shown).
Effect of pure PDGF on progenitor cell growth. When increasing concentrations of pure PDGF were added to cultures containing 5% PDS, a dose-dependent enhancement of CFU-E and BFU-E growth was observed (Fig. 3) . In these experimental conditions, 12.5 ng PDGF/ml gave the maximal stimulatory effect (+60 and +48% for CFU-E and BFU-E growth, respectively). As compared with the usual conditions of growth in 30% FCS, the recovery for BFU-E was lower (71%) than for CFU-E (93%), similar to the recoveries observed in PRS.
The same concentration of PDGF failed to stimulate the growth of peripheral blood BFU-E (Fig. 4) . Cellular requirements for enhancement of erythroid colony growth by PDGF. Optimal concentrations of pure PDGF were then used to investigate the role of adherent cells in the enhancing effect. As shown in Fig. 4 , PDGF failed to stimulate marrow CFU-E or BFU-E growth in the absence of adherent cells. To further define the target cell(s) involved in the response to PDGF, target and potential effector cells were cultured in two layers. Nonadherent marrow cells (1 0), shown to be unresponsive to PDGF (Fig. 4) , were grown in 1% methylcellulose in the overlayer. The underlayer (0.5% agar) contained a pure population of 103 cells known to be present Fig. 5 , the numbers of erythroid colonies and bursts growing in the overlayer were increased significantly in the plates containing PDGF and fibroblasts (+85 and +72% for CFU-E and BFU-E, respectively) or smooth muscle cells (+75 and +58% for CFU-E and BFU-E, respectively). No enhancement of erythroid progenitor cell growth was observed in the cultures with PDGF and endothelial cells. The same culture system was used to study the effect of PDGF on peripheral blood BFU-E growth. Again, peripheral blood BFU-E growth was enhanced by PDGF in the presence N on ad herent morro w c e lIs cultured over specified cell types of fibroblasts or smooth muscle cells, but not with endothelial cells in the underlayer (data not shown).
Discussion
The in vitro observation that serum contains growth-promoting activity for connective tissue cells not present in plasma (11) led to the discovery that platelets contain mitogens that are released during coagulation which stimulate the growth of 3T3 cells (12) , smooth muscle cells (13) , and glial cells (14) . Recently, Dainiak et al. (1) reported that factors released from thrombin-treated platelets and the purified platelet mitogen, PDGF, enhanced human erythropoiesis in vitro.
In the present study, we confirm that serum prepared from PRS supports marrow erythroid colony growth better than serum prepared from PDS (Fig. 2 ). This enhancing effect was similar for both primitive (BFU-E) and mature (CFU-E) erythroid progenitors, suggesting that this growth-promoting activity does not depend on the state of maturation of the progenitor. PRS, however, had no effect on the growth of peripheral blood BFU-E compared with PDS. This suggests that either the circulating stem cells are distinct in their responsiveness or that the target cells for PDGF are not present in peripheral blood.
The effect of PRS could be reproduced, at least in part, by purified PDGF in a dose-dependent fashion (Fig. 3) . This suggested that PDGF is a major mitogenic factor in the PRS. However, with our experimental conditions, the 50% stimulatory effect observed with PRS is due to 0.7 ng PDGF/ml as determined by radioreceptor assay, whereas the same concentration had no detectable effect on colony growth in the doseresponse curve described for pure PDGF. In addition, a monospecific anti-human PDGF antibody only partially reversed the enhancing effects of PRS on erythroid progenitor cell growth (Fig. 2) . These observations suggest that only part of the enhancement by PRS can be ascribed to PDGF. As demonstrated by Heldin and coworkers (15, 16) , platelets contain mitogens that are immunochemically and chemically distinct from PDGF, one of which has been determined to be an epidermal growth factorlike molecule (17) . Activated platelets also release catecholamines (18) and prostaglandins (19) , which stimulate erythroid colony growth (20, 21) .
We have investigated the mechanisms by which pure PDGF influences in vitro erythropoiesis. All cells which respond to PDGF have been shown to contain specific cell surface receptors (2, 3) . No (Fig. 4) . The requirement for adherent cells to detect PDGF enhancement suggests that the action of PDGF is indirect. Although monocytes and macrophages are known to produce erythroid burstpromoting activity (24) , PDGF receptors have not been found on these cells. In addition, although peripheral blood mononuclear cells contain -30% monocytes, neither PRS nor pure PDGF enhanced peripheral blood BFU-E growth (Fig. 4) . PDGF has been shown to specifically stimulate cells of connective tissue origin (2, 3), including adherent or stromal cells, in human long-term marrow cultures from both normal and chronic myelogenous leukemia patients (25) , and these cells may interact with hematopoietic progenitors in the marrow stroma. Consistent with this, the erythroid-enhancing effect of PDGF was restored when fibroblasts and smooth muscle cells were cultured in a two-layer system with nonadherent marrow cells and peripheral blood cells (Fig. 5) . These observations are in accord with a previous report that fibroblasts improved the maintenance of CFU-E in suspension culture (26). Since, in our experiments, marrow and mesenchymal cells were grown in separate layers, stimulation of erythroid colony growth was not related to direct contact between cells, and the PDGF effect is most likely mediated by a diffusable factor.
From these studies we conclude that PDGF acts on erythroid progenitors via the stimulation of mesenchymal cells in marrow stroma and possibly in the vessel wall. Since local platelet activation and release of PDGF would be required in vivo for enhancement by PDGF from platelets, it is unlikely that this system modulates erythropoiesis under normal physiologic conditions. However, it remains to be established whether these in vitro observations might have in vivo relevance in disorders characterized by intravascular coagulation, myelofibrosis, or vasculitis. In addition, since PIDGF-like molecules are produced in vitro by transformed cells (27) (28) (29) (30) , these observations may be pertinent to clonal disorders of the hematopoietic stem cell with abnormal release of cell products. It is also possible that PDGF-like molecules made by endothelial cells (30, 31) , smooth muscle cells during development (32) or after injury (33) , and macrophages (Shimokado, K., E. W. Raines, and R. Ross, submitted for publication), may modulate erythropoiesis within their microenvironments. These observations clearly provide an example of the influence of growth factors in vitro on hematopoietic progenitors via cells of the marrow microenvironment.
